neomycin/polymyxin B/hydrocortisone/bacitracin ophthalmic (Neo-Polycin HC)

Dosing and uses of Neomycin/polymyxin b/hydrocortisone/bacitracin ophthalmic (Neo-Polycin HC)

• Adult
• Pediatric

 

Adult dosage forms and strengths

bacitracin ophthalmic/neomycin/polymyxin B/hydrocortisone

ophthalmic ointment

• 400units/0.35%/10,000units/1%

 

Ocular Inflammation/Infection

Apply thin ribbon of ointment to conjunctival sac of affected eye(s) q3-4hr, depending on severity

 

Pediatric dosage forms and strengths

Safety and efficacy not established

 

Neomycin/polymyxin b/hydrocortisone/bacitracin ophthalmic (Neo-Polycin HC) adverse (side) effects

Frequency not defined

Allergies

Glaucoma

Rash

Superinfection (herpes)

 

Warnings

Contraindications

Hypersensivity to neomycin

Glaucoma

Viral diseases of cornea and conjunctiva (epithelial herpes simplex keratitis, vaccinia, varicella)

Mycobacterial infection of eye & fungal diseases of ocular structures

 

Cautions

Not used much, because of hypersensitivity reactions to neomycin; also, because of steroid component, adequate follow up is essentiaL

Prolonged use or misuse of ocular corticosteroid may result in glaucoma, superinfection (herpes) etc

Newer agents have better steroid & antibiotic coverage

 

Pregnancy and lactation

Pregnancy category: C

Lacation: Unknown

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Neomycin/polymyxin b/hydrocortisone/bacitracin ophthalmic (Neo-Polycin HC)

Mechanism of action

Bacitracin: Inhibits bacterial cell wall synthesis by preventing the incorporation of amino acids and nucleotides into the cell walL

Neomycin: Interferes with bacterial protein synthesis by binding to 30S ribosomal subunits

Polymyxin B: Bactericidal; causes leakage of bacterial membrane

Hydrocortisone: Decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes